These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15838686)

  • 1. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation.
    Klupa T; Edghill EL; Nazim J; Sieradzki J; Ellard S; Hattersley AT; Malecki MT
    Diabetologia; 2005 May; 48(5):1029-31. PubMed ID: 15838686
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
    Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract]   [Full Text] [Related]  

  • 4. Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neonatal diabetes mellitus due to a KCNJ11 R201H mutation.
    Xiao X; Wang T; Li W; Song H; Gong C; Diao C; Yu M; Yuan T; Zhang Y; Sun X; Zhang Q; Lu K; Wang H; Schmitz O; Hansen T
    Horm Metab Res; 2009 Jul; 41(7):580-2. PubMed ID: 19247925
    [No Abstract]   [Full Text] [Related]  

  • 5. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
    Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
    Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
    [No Abstract]   [Full Text] [Related]  

  • 6. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S; Matsuoka H; Yasuda Y; Miyake N; Suzuki K; Yorifuji T; Sugihara S
    J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.
    Heo JW; Kim SW; Cho EH
    Diabetes Res Clin Pract; 2013 Apr; 100(1):e1-2. PubMed ID: 23434183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
    Sagen JV; Raeder H; Hathout E; Shehadeh N; Gudmundsson K; Baevre H; Abuelo D; Phornphutkul C; Molnes J; Bell GI; Gloyn AL; Hattersley AT; Molven A; Søvik O; Njølstad PR
    Diabetes; 2004 Oct; 53(10):2713-8. PubMed ID: 15448106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
    Philla KQ; Bauer AJ; Vogt KS; Greeley SA
    Diabetes Care; 2013 Dec; 36(12):e201. PubMed ID: 24265373
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.
    Stanik J; Gasperikova D; Paskova M; Barak L; Javorkova J; Jancova E; Ciljakova M; Hlava P; Michalek J; Flanagan SE; Pearson E; Hattersley AT; Ellard S; Klimes I
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1276-82. PubMed ID: 17213273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a novel missense mutation, p.P1199L, in the ABCC8 gene.
    Oztekin O; Durmaz E; Kalay S; Flanagan SE; Ellard S; Bircan I
    J Perinatol; 2012 Aug; 32(8):645-7. PubMed ID: 22842804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation.
    Colombo C; Delvecchio M; Zecchino C; Faienza MF; Cavallo L; Barbetti F;
    Diabetologia; 2005 Nov; 48(11):2439-41. PubMed ID: 16205880
    [No Abstract]   [Full Text] [Related]  

  • 15. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
    Doneray H; Houghton J; Tekgunduz KS; Balkir F; Caner I
    J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
    Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
    J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet.
    Delvecchio M; Zecchino C; Faienza MF; Acquafredda A; Barbetti F; Cavallo L
    Diabetes Res Clin Pract; 2009 Jun; 84(3):332-4. PubMed ID: 19345438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.